journal contribution posted on 2021-04-12, 00:10 authored by F Abdelrahman, M Easwaran, OI Daramola, S Ragab, Stephanie LynchStephanie Lynch, TJ Oduselu, FM Khan, A Ayobami, F Adnan, E Torrents, S Sanmukh, A El-Shibiny
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. Due to the global emergence of antibiotic resistance, there has been an increase in research surrounding endolysins as an alternative therapeutic. Endolysins are phage-encoded enzymes, utilized by mature phage virions to hydrolyze the cell wall from within. There is significant evidence that proves the ability of endolysins to degrade the peptidoglycan externally without the assistance of phage. Thus, their incorporation in therapeutic strategies has opened new options for therapeutic application against bacterial infections in the human and veterinary sectors, as well as within the agricultural and biotechnology sectors. While endolysins show promising results within the laboratory, it is important to document their resistance, safety, and immunogenicity for in-vivo application. This review aims to provide new insights into the synergy between endolysins and antibiotics, as well as the formulation of endolysins. Thus, it provides crucial information for clinical trials involving endolysins.
This research is supported by Zewail City of Science and Technology internal Grant No. ZC 019-2019 and ASRT: Genetic Engineering and Biotechnology Grant No: 51/2020. This research and APC is funded by the European Commission under Horizon 2020's Marie Sklodowska-Curie Actions COFUND scheme (Grant Agreement No. 712754) and by the Severo Ochoa program of the Spanish Ministry of Science and Competitiveness [Grant SEV-2014-0425 (2015-2019)]. This study was partially supported by grants from the Ministerio de Economia, Industria y Competitividad, MINECO, and Agencia Estatal de Investigacion (AEI), Spain, co-funded by Fondo Europeo de Desarrollo Regional, FEDER, European Union (RTI2018-098573-B-100), the CERCA programme and AGAUR-Generalitat de Catalunya (2017SGR-1079), Spain, co-funded by the European Regional Development Fund-FEDER and Catalan Cystic Fibrosis association, Spain to E.T.
Article NumberARTN 124
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.